Good morning and welcome to Johnson & Johnson's fourth quarter 2024 earnings conference call. All participants will be in a ...

Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.

Johnson & Johnson (NYSE:JNJ) reported its third-quarter 2024 earnings, surpassing analysts' expectations with an adjusted earnings per share (EPS) of $2.04, slightly above the forecasted $2.02. The ...

"Johnson & Johnson has a longstanding commitment to neuroscience ... be able to obtain these materials (when they are ...

Q4 2024 Earnings Call Transcript January 22, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.04, ...